Pharmacological characterization of the first in class clinical candidate PF-05190457: a selective ghrelin receptor competitive antagonist with inverse agonism that increases vagal afferent firing and glucose-dependent insulin secretion ex vivo.
Saved in:
| Title: | Pharmacological characterization of the first in class clinical candidate PF-05190457: a selective ghrelin receptor competitive antagonist with inverse agonism that increases vagal afferent firing and glucose-dependent insulin secretion ex vivo. |
|---|---|
| Authors: | Kong J; Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA., Chuddy J; Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA., Stock IA; Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA., Loria PM; Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA., Straub SV; Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA., Vage C; Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA., Cameron KO; Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA., Bhattacharya SK; Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA., Lapham K; Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA., McClure KF; Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA., Zhang Y; Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA., Jackson VM; Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA. |
| Source: | British journal of pharmacology [Br J Pharmacol] 2016 May; Vol. 173 (9), pp. 1452-64. Date of Electronic Publication: 2016 Mar 17. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Wiley Country of Publication: England NLM ID: 7502536 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5381 (Electronic) Linking ISSN: 00071188 NLM ISO Abbreviation: Br J Pharmacol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 26784385 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Pharmacological characterization of the first in class clinical candidate PF-05190457: a selective ghrelin receptor competitive antagonist with inverse agonism that increases vagal afferent firing and glucose-dependent insulin secretion ex vivo. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Kong+J%22">Kong J</searchLink>; Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA.<br /><searchLink fieldCode="AU" term="%22Chuddy+J%22">Chuddy J</searchLink>; Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA.<br /><searchLink fieldCode="AU" term="%22Stock+IA%22">Stock IA</searchLink>; Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA.<br /><searchLink fieldCode="AU" term="%22Loria+PM%22">Loria PM</searchLink>; Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA.<br /><searchLink fieldCode="AU" term="%22Straub+SV%22">Straub SV</searchLink>; Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA.<br /><searchLink fieldCode="AU" term="%22Vage+C%22">Vage C</searchLink>; Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA.<br /><searchLink fieldCode="AU" term="%22Cameron+KO%22">Cameron KO</searchLink>; Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA.<br /><searchLink fieldCode="AU" term="%22Bhattacharya+SK%22">Bhattacharya SK</searchLink>; Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA.<br /><searchLink fieldCode="AU" term="%22Lapham+K%22">Lapham K</searchLink>; Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA.<br /><searchLink fieldCode="AU" term="%22McClure+KF%22">McClure KF</searchLink>; Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA.<br /><searchLink fieldCode="AU" term="%22Zhang+Y%22">Zhang Y</searchLink>; Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA.<br /><searchLink fieldCode="AU" term="%22Jackson+VM%22">Jackson VM</searchLink>; Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%227502536%22">British journal of pharmacology</searchLink> [Br J Pharmacol] 2016 May; Vol. 173 (9), pp. 1452-64. <i>Date of Electronic Publication: </i>2016 Mar 17. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley%22">Wiley </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>7502536 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1476-5381 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200071188%22">00071188 </searchLink><i>NLM ISO Abbreviation: </i>Br J Pharmacol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=26784385 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1111/bph.13439 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 1452 Titles: – TitleFull: Pharmacological characterization of the first in class clinical candidate PF-05190457: a selective ghrelin receptor competitive antagonist with inverse agonism that increases vagal afferent firing and glucose-dependent insulin secretion ex vivo. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Kong J – PersonEntity: Name: NameFull: Chuddy J – PersonEntity: Name: NameFull: Stock IA – PersonEntity: Name: NameFull: Loria PM – PersonEntity: Name: NameFull: Straub SV – PersonEntity: Name: NameFull: Vage C – PersonEntity: Name: NameFull: Cameron KO – PersonEntity: Name: NameFull: Bhattacharya SK – PersonEntity: Name: NameFull: Lapham K – PersonEntity: Name: NameFull: McClure KF – PersonEntity: Name: NameFull: Zhang Y – PersonEntity: Name: NameFull: Jackson VM IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 05 Text: 2016 May Type: published Y: 2016 Identifiers: – Type: issn-electronic Value: 1476-5381 Numbering: – Type: volume Value: 173 – Type: issue Value: 9 Titles: – TitleFull: British journal of pharmacology Type: main |
| ResultId | 1 |